Skip to content

Pharmaceuticals

Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Cancer is a bitch. Even if you haven’t had to battle against cancer yourself, you likely know someone who has. Unfortunately for me, that person was my mom; however,…
“Medicine is a science of uncertainty and an art of probability.” – William Osler I think it’s appropriate I start the article by saying that I get it, biotech…
Filament Health (FH.NE) shipped their first batch of good manufacturing practices (GMP) certified natural psilocybin into the United States earlier this week, according to a press release.   The…
Aditxt Inc. (ADTX.Q) announced today that it has signed a letter of intent (LOI) to acquire a biopharmaceutical company commercializing COVID-19 antiviral oral therapy. The target company is currently…
Tonix Pharmaceuticals (TNXP.Q) announced today that it has received the official minutes from a Type B pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA)…
Bioasis is a preclinical biopharmaceutical company focused on research and early-stage development of technologies and products for the treatment of patients with the central nervous system, or CNS, diseases,…
Trillium Therapeutics (TRIL.V) announced today that the Company has entered into a definitive agreement under which Pfizer Inc. will acquire Trillium.     “We’re delighted to announce Pfizer’s proposed…
PharmaCyte Biotech (PMCB.Q) released a statement from Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, on August 16, 2021. In this statement, Mr. Waggoner comments on the Company’s…
AzurRx BioPharma (AZRX.Q) today announced positive topline results from its Phase 2 Combination Trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy…